To the Editor We read with interest the cohort study conducted by Tichelli and colleagues1 of patients who developed a second solid cancer (SSC) after a transplant. Hematopoietic stem cell transplant (HSCT) recipients have a considerable risk of developing secondary solid cancers 5 years or more after HSCT owing to factors such as myeloablative total-body irradiation, young age at HSCT, chronic graft-vs-host disease, and prolonged immunosuppressive treatment longer than 24 months.2,3 Therefore, Inamoto et al4 proposed guidelines to help clinicians provide screening and preventive care for secondary cancers among HSCT recipients.
Vasco M, Napoli C. Guidelines for Secondary Solid Cancers Among HSCT Recipients. JAMA Oncol. 2019;5(7):1064. doi:10.1001/jamaoncol.2019.0617
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.